From venom to veterinary therapeutics: snake venom-derived molecules against antimicrobial-resistant bacteria in the one health era
Abstract
Antimicrobial resistance (AMR) is a major challenge in human and veterinary medicine, diminishing the effectiveness of standard antibiotics against multidrug-resistant (MDR) pathogens. Snake venoms are complex mixtures of proteins, peptides, and enzymes that target biological membranes and cellular functions, but their composition varies with species, population, geography, age, and other biological factors. Numerous venom-derived molecules have demonstrated antibacterial or antibiofilm activity against clinically relevant pathogens, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and resistant Escherichia coli. Prominent candidates include phospholipases A2, L-amino acid oxidases, cathelicidins, crotalicidin-derived peptides, and synthetic analogues. Reported mechanisms include membrane disruption, oxidative stress, prevention of biofilm formation, and, for selected agents, activity against established biofilms. Although membrane-active peptides may complement conventional antibiotics, direct quantitative evidence of synergy for snake-venom-derived candidates remains limited and requires standardised combination testing. Native toxins may also exhibit cytotoxicity, haemolysis, poor pharmacokinetics, and batch variability; consequently, rational peptide engineering, defined synthetic production, delivery systems, and comparative selectivity-index assessment are central to translation. This mini-manuscript summarises recent progress, distinguishes preventive from eradicative antibiofilm effects, evaluates the predominantly preclinical evidence relevant to veterinary medicine, and discusses One Health opportunities and practical barriers.